Regeneron Pharmaceuticals, Inc.
REGN
$895.17
$2.690.30%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 1.16B | 1.01B | 968.40M | 817.80M | 1.20B |
| Total Depreciation and Amortization | 113.00M | 105.40M | 103.10M | 99.50M | 100.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -121.50M | 193.40M | 32.20M | 209.40M | 40.70M |
| Change in Net Operating Assets | -61.40M | -192.30M | -81.30M | 240.90M | 382.00M |
| Cash from Operations | 1.09B | 1.11B | 1.02B | 1.37B | 1.72B |
| Capital Expenditure | -251.40M | -176.00M | -113.00M | -178.20M | -152.20M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -3.80M | -51.10M | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 189.00M | -269.20M | -2.27B | -57.50M | -1.71B |
| Cash from Investing | -66.20M | -496.30M | -2.39B | -235.70M | -1.86B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 301.00M | 268.60M | 90.70M | 485.20M | 372.60M |
| Repurchase of Common Stock | -747.10M | -675.90M | -704.90M | -807.70M | -620.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -446.10M | -407.30M | -614.20M | -322.50M | -247.60M |
| Foreign Exchange rate Adjustments | 200.00K | -200.00K | -400.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 577.60M | 210.50M | -1.98B | 809.40M | -385.40M |
